641 related articles for article (PubMed ID: 17042762)
21. Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34+ cell dose measured pre-freeze in patients that receive more than 2x10(6) CD34+ cells/kg.
Abrahamsen JF; Wentzel-Larsen T; Bruserud O
Cytotherapy; 2004; 6(4):356-62. PubMed ID: 16146888
[TBL] [Abstract][Full Text] [Related]
22. A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis.
Gandhi M; Jestice H; Scott M; Bloxham D; Bass G; Craig J; Marcus R
Bone Marrow Transplant; 1999 Aug; 24(4):369-75. PubMed ID: 10467325
[TBL] [Abstract][Full Text] [Related]
23. A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34+ cells/kg be considered the minimum threshold?
Singhal S; Powles R; Treleaven J; Kulkarni S; Sirohi B; Horton C; Millar B; Shepherd V; Tait D; Saso R; Rowland A; Long S; Mehta J
Bone Marrow Transplant; 2000 Sep; 26(5):489-96. PubMed ID: 11019837
[TBL] [Abstract][Full Text] [Related]
24. Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection.
Peggs KS; Verfuerth S; Pizzey A; Khan N; Moss P; Goldstone AH; Yong K; Mackinnon S
Biol Blood Marrow Transplant; 2003 Mar; 9(3):198-205. PubMed ID: 12652471
[TBL] [Abstract][Full Text] [Related]
25. An antecedent diagnosis of refractory anemia with excess blasts has no influence on mobilization of peripheral blood stem cells and hematopoietic recovery after autologous stem cell transplantation in acute myeloid leukemia.
Viola A; Falco C; D'Elia R; D'Amico MR; Vicari L; Tambaro FP; Correale P; Laudati D; Palmieri S; Ferrara F
Eur J Haematol; 2007 Jan; 78(1):41-7. PubMed ID: 17042770
[TBL] [Abstract][Full Text] [Related]
26. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
27. Role of the CD34+ 38- cells in posttransplant hematopoietic recovery.
Hénon P; Sovalat H; Bourderont D; Ojeda-Uribe M; Arkam Y; Wunder E; Raidot JP; Husseini F; Audhuy B
Stem Cells; 1998; 16 Suppl 1():113-22. PubMed ID: 11012153
[TBL] [Abstract][Full Text] [Related]
28. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
[TBL] [Abstract][Full Text] [Related]
29. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.
Steidl U; Fenk R; Bruns I; Neumann F; Kondakci M; Hoyer B; Gräf T; Rohr UP; Bork S; Kronenwett R; Haas R; Kobbe G
Bone Marrow Transplant; 2005 Jan; 35(1):33-6. PubMed ID: 15531906
[TBL] [Abstract][Full Text] [Related]
30. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
31. Large-scale expansion and transplantation of CD34(+) hematopoietic cells: in vitro and in vivo confirmation of neutropenia abrogation related to the expansion process without impairment of the long-term engraftment capacity.
Boiron JM; Dazey B; Cailliot C; Launay B; Attal M; Mazurier F; McNiece IK; Ivanovic Z; Caraux J; Marit G; Reiffers J
Transfusion; 2006 Nov; 46(11):1934-42. PubMed ID: 17076849
[TBL] [Abstract][Full Text] [Related]
32. First and second apheresis in patients with multiple myeloma: no differences in tumor load and hematopoietic stem cell yield.
Kiel K; Cremer FW; Ehrbrecht E; Wallmeier M; Hegenbart U; Goldschmidt H; Moos M
Bone Marrow Transplant; 1998 Jun; 21(11):1109-15. PubMed ID: 9645573
[TBL] [Abstract][Full Text] [Related]
33. Role of CD34+ cells in engraftment after high-dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue.
Millar BC; Millar JL; Bell JB; Raje N; Milan S; Mehta J; Singhal S; Middleton GW; Sheperd V; Catovsky D; Powles RL
Bone Marrow Transplant; 1996 Nov; 18(5):871-8. PubMed ID: 8932839
[TBL] [Abstract][Full Text] [Related]
34. Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies.
Carral A; de la Rubia J; Martín G; Martínez J; Sanz G; Jarque I; Sempere A; Soler MA; Marty ML; Sanz MA
Bone Marrow Transplant; 2002 May; 29(10):825-32. PubMed ID: 12058232
[TBL] [Abstract][Full Text] [Related]
35. Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device--a local experience.
Leong CF; Habsah A; Teh HS; Goh KY; Fadilah SA; Cheong SK
Malays J Pathol; 2008 Jun; 30(1):31-6. PubMed ID: 19108409
[TBL] [Abstract][Full Text] [Related]
36. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
Tarella C; Di Nicola M; Caracciolo D; Zallio F; Cuttica A; Omedè P; Bondesan P; Magni M; Matteucci P; Gallamini A; Pileri A; Gianni AM
Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694
[TBL] [Abstract][Full Text] [Related]
37. Autologous peripheral blood progenitor cells cryopreserved with 5 and 10 percent dimethyl sulfoxide alone give comparable hematopoietic reconstitution after transplantation.
Akkök CA; Liseth K; Nesthus I; Løkeland T; Tefre K; Bruserud O; Abrahamsen JF
Transfusion; 2008 May; 48(5):877-83. PubMed ID: 18298599
[TBL] [Abstract][Full Text] [Related]
38. Platelet transfusion requirements during autologous peripheral blood progenitor cell transplantation correlate with the pretransplant platelet count.
Bolwell BJ; Goormastic M; Andresen S; Overmoyer B; Pohlman B; Kalaycio M
Bone Marrow Transplant; 1997 Sep; 20(6):459-63. PubMed ID: 9313878
[TBL] [Abstract][Full Text] [Related]
39. Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).
Ergene U; Cağirgan S; Pehlivan M; Yilmaz M; Tombuloğlu M
Transfus Apher Sci; 2007 Feb; 36(1):23-9. PubMed ID: 17292672
[TBL] [Abstract][Full Text] [Related]
40. T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation.
Baron F; Schaaf-Lafontaine N; Humblet-Baron S; Meuris N; Castermans E; Baudoux E; Frère P; Bours V; Fillet G; Beguin Y
Transplantation; 2003 Dec; 76(12):1705-13. PubMed ID: 14688520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
